Antiproliferative action of vitamin D-related compounds and insulin- like growth factor-binding protein 5 accumulation

Journal of the National Cancer Institute

Volumn 89, Issue 9, 1997, Pages 652-656

  Rozen, Florence ^a   Yang, Xiao Feng ^a   Huynh, Hung ^a   Pollak, Michael ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Cancer Prevention Research Unit   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; LEXACALCITOL; MESSENGER RNA; SEOCALCITOL; SOMATOMEDIN BINDING PROTEIN 5; VITAMIN D DERIVATIVE;

ARTICLE; CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING;

EID: 0030957217     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.9.652     Document Type: Article

References (43)

1. Eisman JA, Martin TJ, MacIntyre I, Frampton RJ, Moseley JM, Whitehead R. 1,25-Dihydroxyvitamin D3 receptor in a cultured human breast cancer cell line (MCF 7 cells). Biochem Biophys Res Commun 1980;93:9-15.
2. Colston K, Colston MJ, Fieldsteel AH, Feldman D. 1,25-Dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res 1982;42:856-9.
3. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989;1:188-91.
4. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992; 13:719-64.
5. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992;44:2273-80.
6. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic M, Koeffler HP. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A 1990;87:3929-32.
7. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, et al. 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55:2822-30.
8. James SY, Mackay AG, Binderup L, Colston KW. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 1994;141:555-63.
9. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda K. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832-7.
10. 2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 1991;78:75-82.
11. Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 1992;13:765-84.
12. Abe J, Takita Y, Nakano T, Miyaura C, Suda T, Nishii Y. A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 1989;124:2645-7.
13. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988;85:3294-8.
14. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, et al. Two nuclear signalling pathways for vitamin D. Nature 1993;361:657-60.
15. Ozono K, Liao J, Kerner SA, Scott RA, Pike JW. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J Biol Chem 1990;265:21881-8.
16. Darwish HM, DeLuca HF. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol 1996;53:321-44.
17. Pike JW, Gooze LL, Haussler MR. Biochemical evidence for 1,25-dihydroxyvitamin D receptor macromolecules in parathyroid, pancreatic, pituitary, and placental tissues. Life Sci 1980;26:407-14.
18. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994;31:191-202.
19. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, et al. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxy-vitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 1991;51: 239-44.
20. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995;55:249-52.
21. Yang XF, Beamer WG, Huynh HT, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 1996;56:1509-11.
22. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
23. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56:1545-50.
24. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270:13589-92.
25. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193-8.
26. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016-21.
27. Pratt SE, Pollak MN. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994;198: 292-7.
28. Huynh HT, Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res 1994;54:3115-9.
29. Shimasaki S, Shimonaka M, Zhang HP, Ling N. Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem 1991;266:10646-53.
30. Huynh HT, Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 1993;53: 5585-8.
31. Huynh HT, Nickerson T, Pollak M, Yang XF. Regulation of insulin-like growth factor I receptor gene expression by the pure antiestrogen ICI 182780. Clin Cancer Res 1996;2:2037-42.
32. McGuire WL Jr, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action [published erratum appears in J Natl Cancer Inst 1992:84:1837]. J Natl Cancer Inst 1992;84:1336-41.
33. Camacho-Hubner C, Busby WH Jr, McCusker RH, Wright G, Clemmons DR. Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J Biol Chem 1992;267:11949-56.
34. Conover CA, Kiefer MC. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. J Clin Endocrinol Metab 1993; 76:1153-9.
35. Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 1992;8:213-23.
36. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9.
37. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995;55:2463-9.
38. Huynh HT, Yang XF, Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 1996;7: 1501-6.
39. Allander SV, Larsson C, Ehrenborg E, Suwan ichkul A, Weber G, Morris SL, et al. Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5. J Biol Chem 1994;269: 10891-8.
40. Tonner E, Quarrie L, Travers M, Barber M, Logan A, Wilde C, et al. Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Prog Growth Factor Res 1995;6:409-14.
41. Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992;52:4973-8.
42. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res 1994;54:6334-7.
43. Narvaez CJ, Vanweelden K, Byrne I, Welsh J. Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 1996;137: 400-9.